VERU INC (VERU) Stock Price & Overview
NASDAQ:VERU • US92536C2026
Current stock price
The current stock price of VERU is 2.48 USD. Today VERU is up by 3.33%. In the past month the price increased by 0.81%. In the past year, price decreased by -54.3%.
VERU Key Statistics
- Market Cap
- 39.804M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.16
- Dividend Yield
- N/A
VERU Stock Performance
VERU Stock Chart
VERU Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to VERU. When comparing the yearly performance of all stocks, VERU is a bad performer in the overall market: 87.36% of all stocks are doing better.
VERU Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VERU. No worries on liquidiy or solvency for VERU as it has an excellent financial health rating, but there are worries on the profitability.
VERU Earnings
VERU Forecast & Estimates
8 analysts have analysed VERU and the average price target is 25.5 USD. This implies a price increase of 928.23% is expected in the next year compared to the current price of 2.48.
For the next year, analysts expect an EPS growth of 45.84% and a revenue growth -100% for VERU
VERU Groups
Sector & Classification
VERU Financial Highlights
Over the last trailing twelve months VERU reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 55.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.18% | ||
| ROE | -51.49% | ||
| Debt/Equity | 0 |
VERU Ownership
VERU Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.64 | 878.353B | ||
| JNJ | JOHNSON & JOHNSON | 20.47 | 574.237B | ||
| MRK | MERCK & CO. INC. | 23.05 | 294.907B | ||
| PFE | PFIZER INC | 9.08 | 154.155B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.11 | 117.443B | ||
| ZTS | ZOETIS INC | 16.5 | 49.305B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.07 | 27.037B | ||
| VTRS | VIATRIS INC | 5.25 | 15.152B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.67 | 11.336B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.631B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.37B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.073B | ||
| CORT | CORCEPT THERAPEUTICS INC | 50.46 | 4.435B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VERU
Company Profile
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. The company is headquartered in Miami, Florida and currently employs 20 full-time employees. Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Company Info
IPO: 1990-07-19
VERU INC
2916 N. Miami Avenue, Suite 1000
Miami FLORIDA 33127 US
CEO: Mitchell S. Steiner
Employees: 20
Phone: 13125959123
VERU INC / VERU FAQ
Can you describe the business of VERU INC?
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. The company is headquartered in Miami, Florida and currently employs 20 full-time employees. Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Can you provide the latest stock price for VERU INC?
The current stock price of VERU is 2.48 USD. The price increased by 3.33% in the last trading session.
Does VERU INC pay dividends?
VERU does not pay a dividend.
What is the ChartMill technical and fundamental rating of VERU stock?
VERU has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about VERU INC (VERU) stock?
8 analysts have analysed VERU and the average price target is 25.5 USD. This implies a price increase of 928.23% is expected in the next year compared to the current price of 2.48.
Can you provide the upcoming earnings date for VERU INC?
VERU INC (VERU) will report earnings on 2026-05-06.
Can you provide the short interest for VERU stock?
The outstanding short interest for VERU INC (VERU) is 4.98% of its float.